One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, ...

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

In light of the recent understanding of the molecular complexity of cancer and the costs of corresponding targeted treatments such as immunotherapies and CAR-T, there are legitimate questions that ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management. The new ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anitocabtagene autoleucel (anito-cel) which is being prepared for a filing and potential ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

I often speak with leaders across the life sciences ecosystem who are all grappling with the same truth: our current method of drug development has hit a wall. Despite historic breakthroughs in ...

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion. The wide-ranging ...